Immuneering
IMRX
112 hedge funds and large institutions have $172M invested in Immuneering in 2026 Q2 according to their latest regulatory filings, with 38 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 21 closing their positions.
167% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $1.15M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
81% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 21
67% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 21
18% more funds holding
Funds holding: 95 → 112 (+17)
11% more capital invested
Capital invested by funds: $154M → $172M (+$17.4M)
7.92% more ownership
Funds ownership: 45.33% → 53.25% (+7.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$3.71M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$3.71M |
| 4 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$3.28M |
| 5 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.4M |
| 2 |
Millennium Management
New York
|
-$3.91M |
| 3 |
OCM
Occam Crest Management
Darien,
Connecticut
|
-$1.35M |
| 4 |
Goldman Sachs
New York
|
-$1.17M |
| 5 |
DC
Diametric Capital
Boston,
Massachusetts
|
-$922K |
IMRX Hedge Fund Activity: Q2 2026 in Review
112 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q2 2026, worth a combined $172M — up 11% from $154M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new IMRX positions and 21 closed out — a net gain of 17 holders — while 35 added to existing stakes and 21 trimmed.
The largest buyer was BlackRock, adding an estimated $14.5M. The largest seller was Marshall Wace, cutting an estimated $6.4M.
- 112 institutional investors held Immuneering (IMRX) as of Q2 2026, up from 95 in Q1 2026.
- Funds reported $172M of Immuneering stock for Q2 2026, up 11% quarter-over-quarter.
- 38 funds opened new Immuneering positions in Q2 2026 and 21 closed out, a net change of +17 holders.
- The largest Immuneering buyer in Q2 2026 was BlackRock, an estimated $14.5M added.
- The largest Immuneering seller in Q2 2026 was Marshall Wace, an estimated $6.4M sold.
Based on aggregated 13F filings for Q2 2026.